Results 31 to 40 of about 14,827 (208)

Continuous subcutaneous apomorphine monotherapy in Parkinson’s disease

Annals of Agricultural and Environmental Medicine, 2019
Introduction and objective Continuous subcutaneous apomorphine (APO) treatment is one of the 3 therapeutic options for advanced Parkinson’s disease (PD), in addition to deep brain stimulation (DBS) and intrajejunal levodopa.
Ewa Papuć, Olga Trzciniecka, Konrad Rejdak   +2 more
doaj   +1 more source

Relationship of Dopamine of the Nucleus Accumbens with Intra-infralimbic Apomorphine Microinjection [PDF]

Iranian Journal of Basic Medical Sciences, 2013
Objective(s): The dopamine level of the nucleus accumbens changes during some stereotyped behaviors. To study dopamine level of the nucleus accumbens in intra infralimbic apomorphine-induced climbing, microdialysis probes were implanted into the nucleus ...
Abbas Alimoradian, Javad Sajedianfard*, Faegheh Baha-aldini Beigy, Mohammad Reza Panjehshahin, Ali Akbar Owji   +4 more
doaj  

TAB2 Causes Neuronal Damage by Aggravating Microglia‐Mediated Neuroinflammation in Parkinson's Disease

Advanced Science, EarlyView.
In microglia, STAT3 upregulates TAB2, which promotes NF‐κB activation through its NZF domain‐mediated recognition of K63‐linked ubiquitin chains, leading to inflammatory cytokine release and subsequent neuronal injury. Lumacaftor suppresses TAB2 expression and directly binds the TAB2‐NZF domain to interrupt K63 ubiquitin recognition, thereby blocking ...
Yanhao Zhao, Zimeng Huang, Jianing Gao, Aolan Li, Huizhi Wang, Yingchuan Chen, Guanyu Zhu, Xin Zhang, Yin Jiang, Moxuan Zhang, Fangang Meng, Jianguo Zhang, Tingting Du   +12 more
wiley   +1 more source

Modulation of the TGF‐β/Smad Signaling Pathway by a Bioactive Oxidized Polygonati Rhizoma Polysaccharide Crosslinked Chitosan Hydrogel as Therapeutic Carrier for Parkinson's Disease Treatment

Advanced Science, EarlyView.
An injectable, self‐healing COPRP hydrogel integrates structurally defined oxidized Polygonati rhizoma polysaccharide with carboxymethyl chitosan through dynamic Schiff‐base crosslinking. The bioactive matrix scavenges reactive oxygen species, suppresses neuroinflammation, protects dopaminergic neurons, and supports sustained levodopa release.
Peng Dai, Jikuang Zhao, Chang Xue, Kailei Xu, Liang Yong, Zhuangwei Zhang, Yi Huang, Jianwei Shuai, Xianzhen Chen, Sheng Nie, Junpeng Xu   +10 more
wiley   +1 more source

Increased Serum Lithium Level due to Mild to Moderate damage to Dopaminergic Neurons of the Substantia Nigra, Evidence from Animal Model of Parkinson’s Disease induced by 6-Hydoxydopamine

مجله علمی دانشگاه علوم پزشکی کردستان, 2022
Background and Aim. It has been reported that lithium (Li) has neuroprotective effects in neurodegenerative diseases. In this study, we investigated the association between serum Li level and Parkinson’s disease induced by 6-hydroxypapamine (6-OHDA) in ...
Mohammad Hossein Esmaeili, Hashem Haghdoost-Yazdi, Milad Mazaheri   +2 more
doaj  

Attenuation of age-related cognitive decline and memory deficits through apomorphine administration

Pakistan Journal of Pharmaceutical Sciences
Oxidative stress, stemming from heightened production of reactive oxygen species and free radicals, significantly contributes to the aging process. Apomorphine emerges as a pivotal medication for managing Alzheimer’s, Parkinson’s, and other age-related ...
Huma Ikram, Rumaisa Zakir, Darakhshan Jabeen Haleem, Karachi, Pakistan   +4 more
doaj   +1 more source

The Role of Genetic Data in Selecting Device-Aided Therapies in Patients With Advanced Parkinson’s Disease: A Mini-Review

Frontiers in Aging Neuroscience, 2022
Parkinson’s disease (PD) is a common neurodegenerative disease. At present, 5–10% of PD patients are found to have monogenic form of the disease. Each genetic mutation has its own unique clinical features and disease trajectory.
Germaine Hiu-Fai Chan
doaj   +1 more source

Histamine and the mechanisms of nausea and vomiting: Translating the uncertain pharmacology of cyclizine

British Journal of Clinical Pharmacology, EarlyView.
Abstract Cyclizine is a long‐established, short‐acting drug, registered for preventing motion sickness, post‐operative nausea and vomiting (PONV) and ‘vomiting of known cause’. The latter is not defined but may include pregnancy and patients receiving palliative care, historically accepted without large, controlled trials.
Gareth J. Sanger, Paul L. R. Andrews
wiley   +1 more source

Inhibition of protein kinase activity by apomorphine.

, 1986
The effect of apomorphine (1-20 microM) on protein kinase activity was studied in extracts from rat peritoneal mast cells and brain tissue. Apomorphine inhibited the cyclic AMP-dependent and the calcium-plus phosphatidylserine-dependent protein kinase ...
Battistella A, Bellini F, Bruni A, PALATINI, PIETRO, Toffano G.   +4 more
core   +1 more source

Integrating technology into a successful apomorphine delivery program in Thailand: a 10-year journey of achievements with a five-motto concept

Frontiers in Neurology
IntroductionApomorphine, a potent dopamine agonist, is a therapeutic option for patients with Parkinson’s disease and motor fluctuations. However, the adoption of and adherence to this therapy have been limited by the need for complex delivery devices ...
Onanong Phokaewvarangkul, Nithinan Kantachadvanich, Vijittra Buranasrikul, Kanyawat Sanyawut, Saisamorn Phumphid, Chanawat Anan, Roongroj Bhidayasiri, Roongroj Bhidayasiri   +7 more
doaj   +1 more source